Logo image of CSTM

CONSTELLIUM SE (CSTM) Stock Fundamental Analysis

USA - NYSE:CSTM - FR0013467479 - Common Stock

15.44 USD
0 (0%)
Last: 10/3/2025, 8:04:01 PM
15.44 USD
0 (0%)
After Hours: 10/3/2025, 8:04:01 PM
Fundamental Rating

4

Overall CSTM gets a fundamental rating of 4 out of 10. We evaluated CSTM against 156 industry peers in the Metals & Mining industry. While CSTM is still in line with the averages on profitability rating, there are concerns on its financial health. CSTM is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

CSTM had positive earnings in the past year.
CSTM had a positive operating cash flow in the past year.
CSTM had positive earnings in 4 of the past 5 years.
In the past 5 years CSTM always reported a positive cash flow from operatings.
CSTM Yearly Net Income VS EBIT VS OCF VS FCFCSTM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

1.2 Ratios

CSTM has a better Return On Assets (2.44%) than 65.38% of its industry peers.
Looking at the Return On Equity, with a value of 16.83%, CSTM belongs to the top of the industry, outperforming 89.74% of the companies in the same industry.
CSTM's Return On Invested Capital of 11.15% is amongst the best of the industry. CSTM outperforms 87.18% of its industry peers.
CSTM had an Average Return On Invested Capital over the past 3 years of 8.33%. This is below the industry average of 12.87%.
The 3 year average ROIC (8.33%) for CSTM is below the current ROIC(11.15%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.44%
ROE 16.83%
ROIC 11.15%
ROA(3y)3.45%
ROA(5y)3.08%
ROE(3y)23.43%
ROE(5y)N/A
ROIC(3y)8.33%
ROIC(5y)8.11%
CSTM Yearly ROA, ROE, ROICCSTM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100 -150

1.3 Margins

The Profit Margin of CSTM (0.99%) is better than 62.18% of its industry peers.
CSTM's Profit Margin has declined in the last couple of years.
CSTM has a Operating Margin (3.72%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of CSTM has declined.
With a Gross Margin value of 12.18%, CSTM perfoms like the industry average, outperforming 45.51% of the companies in the same industry.
CSTM's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 3.72%
PM (TTM) 0.99%
GM 12.18%
OM growth 3Y-14.91%
OM growth 5Y-4.66%
PM growth 3Y-43.25%
PM growth 5Y-5.23%
GM growth 3Y6.67%
GM growth 5Y5.15%
CSTM Yearly Profit, Operating, Gross MarginsCSTM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 -10

2

2. Health

2.1 Basic Checks

CSTM has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
CSTM has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, CSTM has more shares outstanding
CSTM has a worse debt/assets ratio than last year.
CSTM Yearly Shares OutstandingCSTM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
CSTM Yearly Total Debt VS Total AssetsCSTM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

CSTM has an Altman-Z score of 3.23. This indicates that CSTM is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.23, CSTM is in line with its industry, outperforming 49.36% of the companies in the same industry.
CSTM has a Debt/Equity ratio of 2.53. This is a high value indicating a heavy dependency on external financing.
CSTM has a Debt to Equity ratio of 2.53. This is amonst the worse of the industry: CSTM underperforms 92.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.53
Debt/FCF N/A
Altman-Z 3.23
ROIC/WACC1.32
WACC8.42%
CSTM Yearly LT Debt VS Equity VS FCFCSTM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

CSTM has a Current Ratio of 1.23. This is a normal value and indicates that CSTM is financially healthy and should not expect problems in meeting its short term obligations.
CSTM has a worse Current ratio (1.23) than 78.85% of its industry peers.
CSTM has a Quick Ratio of 1.23. This is a bad value and indicates that CSTM is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.53, CSTM is doing worse than 89.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 0.53
CSTM Yearly Current Assets VS Current LiabilitesCSTM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

6

3. Growth

3.1 Past

CSTM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -73.49%.
Measured over the past 5 years, CSTM shows a small growth in Earnings Per Share. The EPS has been growing by 3.27% on average per year.
The Revenue has grown by 80.43% in the past year. This is a very strong growth!
Measured over the past years, CSTM shows a small growth in Revenue. The Revenue has been growing by 4.43% on average per year.
EPS 1Y (TTM)-73.49%
EPS 3Y-38.65%
EPS 5Y3.27%
EPS Q2Q%-53.96%
Revenue 1Y (TTM)80.43%
Revenue growth 3Y6.04%
Revenue growth 5Y4.43%
Sales Q2Q%3.35%

3.2 Future

CSTM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 67.98% yearly.
Based on estimates for the next years, CSTM will show a quite strong growth in Revenue. The Revenue will grow by 13.36% on average per year.
EPS Next Y167.79%
EPS Next 2Y101.65%
EPS Next 3Y67.98%
EPS Next 5YN/A
Revenue Next Year15.8%
Revenue Next 2Y10.61%
Revenue Next 3Y13.36%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CSTM Yearly Revenue VS EstimatesCSTM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2B 4B 6B 8B
CSTM Yearly EPS VS EstimatesCSTM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2

6

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 53.24, CSTM can be considered very expensive at the moment.
62.82% of the companies in the same industry are more expensive than CSTM, based on the Price/Earnings ratio.
CSTM is valuated expensively when we compare the Price/Earnings ratio to 27.86, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 9.24, the valuation of CSTM can be described as very reasonable.
Based on the Price/Forward Earnings ratio, CSTM is valued cheaply inside the industry as 90.38% of the companies are valued more expensively.
CSTM's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.32.
Industry RankSector Rank
PE 53.24
Fwd PE 9.24
CSTM Price Earnings VS Forward Price EarningsCSTM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CSTM indicates a rather cheap valuation: CSTM is cheaper than 92.95% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 5.25
CSTM Per share dataCSTM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of CSTM may justify a higher PE ratio.
A more expensive valuation may be justified as CSTM's earnings are expected to grow with 67.98% in the coming years.
PEG (NY)0.32
PEG (5Y)16.3
EPS Next 2Y101.65%
EPS Next 3Y67.98%

0

5. Dividend

5.1 Amount

CSTM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CONSTELLIUM SE

NYSE:CSTM (10/3/2025, 8:04:01 PM)

After market: 15.44 0 (0%)

15.44

0 (0%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)07-29 2025-07-29/bmo
Earnings (Next)10-22 2025-10-22/bmo
Inst Owners87.53%
Inst Owner Change-0.02%
Ins Owners1.78%
Ins Owner ChangeN/A
Market Cap2.27B
Analysts82.22
Price Target19.38 (25.52%)
Short Float %2.85%
Short Ratio3.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)129.83%
Min EPS beat(2)-17.42%
Max EPS beat(2)277.07%
EPS beat(4)1
Avg EPS beat(4)-188.59%
Min EPS beat(4)-952.86%
Max EPS beat(4)277.07%
EPS beat(8)2
Avg EPS beat(8)-110.02%
EPS beat(12)3
Avg EPS beat(12)-76.02%
EPS beat(16)5
Avg EPS beat(16)-28.44%
Revenue beat(2)1
Avg Revenue beat(2)-1.4%
Min Revenue beat(2)-5.83%
Max Revenue beat(2)3.03%
Revenue beat(4)1
Avg Revenue beat(4)-3.56%
Min Revenue beat(4)-9.9%
Max Revenue beat(4)3.03%
Revenue beat(8)2
Avg Revenue beat(8)-3.1%
Revenue beat(12)4
Avg Revenue beat(12)-1.8%
Revenue beat(16)8
Avg Revenue beat(16)0.42%
PT rev (1m)0%
PT rev (3m)10.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.6%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.92%
Revenue NY rev (1m)-0.2%
Revenue NY rev (3m)3.72%
Valuation
Industry RankSector Rank
PE 53.24
Fwd PE 9.24
P/S 0.17
P/FCF N/A
P/OCF 9.51
P/B 2.91
P/tB 3.54
EV/EBITDA 5.25
EPS(TTM)0.29
EY1.88%
EPS(NY)1.67
Fwd EY10.82%
FCF(TTM)-1.05
FCFYN/A
OCF(TTM)1.62
OCFY10.52%
SpS90.29
BVpS5.31
TBVpS4.36
PEG (NY)0.32
PEG (5Y)16.3
Profitability
Industry RankSector Rank
ROA 2.44%
ROE 16.83%
ROCE 14.12%
ROIC 11.15%
ROICexc 11.59%
ROICexgc 12.1%
OM 3.72%
PM (TTM) 0.99%
GM 12.18%
FCFM N/A
ROA(3y)3.45%
ROA(5y)3.08%
ROE(3y)23.43%
ROE(5y)N/A
ROIC(3y)8.33%
ROIC(5y)8.11%
ROICexc(3y)8.79%
ROICexc(5y)8.68%
ROICexgc(3y)9.69%
ROICexgc(5y)9.98%
ROCE(3y)10.54%
ROCE(5y)10.26%
ROICexcg growth 3Y-18.02%
ROICexcg growth 5Y-6.42%
ROICexc growth 3Y-13.61%
ROICexc growth 5Y-3.24%
OM growth 3Y-14.91%
OM growth 5Y-4.66%
PM growth 3Y-43.25%
PM growth 5Y-5.23%
GM growth 3Y6.67%
GM growth 5Y5.15%
F-Score7
Asset Turnover2.47
Health
Industry RankSector Rank
Debt/Equity 2.53
Debt/FCF N/A
Debt/EBITDA 2.49
Cap/Depr 131.4%
Cap/Sales 2.96%
Interest Coverage 6
Cash Conversion 30.1%
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 0.53
Altman-Z 3.23
F-Score7
WACC8.42%
ROIC/WACC1.32
Cap/Depr(3y)117.66%
Cap/Depr(5y)102.03%
Cap/Sales(3y)4.56%
Cap/Sales(5y)4.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-73.49%
EPS 3Y-38.65%
EPS 5Y3.27%
EPS Q2Q%-53.96%
EPS Next Y167.79%
EPS Next 2Y101.65%
EPS Next 3Y67.98%
EPS Next 5YN/A
Revenue 1Y (TTM)80.43%
Revenue growth 3Y6.04%
Revenue growth 5Y4.43%
Sales Q2Q%3.35%
Revenue Next Year15.8%
Revenue Next 2Y10.61%
Revenue Next 3Y13.36%
Revenue Next 5YN/A
EBIT growth 1Y29.69%
EBIT growth 3Y-9.78%
EBIT growth 5Y-0.44%
EBIT Next Year108.99%
EBIT Next 3Y38.47%
EBIT Next 5YN/A
FCF growth 1Y-224.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.65%
OCF growth 3Y-5.53%
OCF growth 5Y-7.6%